Shares of GE HealthCare (GEHC.O) declined sharply today, reaching a 20-day low as investors reacted to recent developments in the company's cardiac imaging technology. Despite the announcement of an expansion of the Flyrcado™ usage by Cardiovascular Associates of America (CVAUSA) across 25 sites, the stock's bearish momentum suggests market concerns may outweigh positive news.
The technical breakdown below the 20-day low indicates increased selling pressure, potentially signaling a shift in investor sentiment. This comes in the wake of a successful pilot program that demonstrated Flyrcado's effectiveness in enhancing myocardial perfusion imaging, as noted by Dr. Edmund Coyne.
While GE HealthCare's commitment to innovation and its strategic focus on personalized healthcare solutions remain strong, the upcoming investor conference presentation by CFO Jay Saccaro may provide further insights into the company's growth strategy amidst competitive pressures, including a recent FDA approval for a rival's X-Ray contrast product. Investors will be closely monitoring these developments as they assess the future trajectory of GE HealthCare's stock.
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 78.780
Low
80.00
Averages
92.25
High
105.00
Current: 78.780
Low
80.00
Averages
92.25
High
105.00
Piper Sandler
Overweight
maintain
$91 -> $94
2026-01-30
New
Reason
Piper Sandler
Price Target
$91 -> $94
AI Analysis
2026-01-30
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on GE HealthCare to $94 from $91 and keeps an Overweight rating on the shares. The firm believes the Q4 setup tilts positive after shares have pulled back in recent weeks on Flyrcado guidance uncertainty.
Jefferies
Jay Saccaro
maintain
$95 -> $105
2025-12-11
Reason
Jefferies
Jay Saccaro
Price Target
$95 -> $105
2025-12-11
maintain
Reason
Jefferies raised the firm's price target on GE HealthCare to $105 from $95 and keeps a Buy rating on the shares after having hosted a call with CFO Jay Saccaro and other executives. The firm, which was "encouraged" by GE HealthCare's Q3 performance and leading indicators, sees stable to improving fundamentals and "a strong catalyst path" with consensus appearing to model very little contribution from Flyrcado or Vizamyl/Cerianna, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GEHC
Unlock Now
Citi
Neutral
maintain
$83 -> $88
2025-12-11
Reason
Citi
Price Target
$83 -> $88
2025-12-11
maintain
Neutral
Reason
Citi raised the firm's price target on GE HealthCare to $88 from $83 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Wells Fargo
Larry Biegelsen
Overweight
maintain
$89 -> $87
2025-10-30
Reason
Wells Fargo
Larry Biegelsen
Price Target
$89 -> $87
2025-10-30
maintain
Overweight
Reason
Wells Fargo analyst Larry Biegelsen lowered the firm's price target on GE HealthCare to $87 from $89 and keeps an Overweight rating on the shares. The firm notes the company delivered a beat on the top line and EPS of $1.07 was ahead of both consensus and Wells Fargo's estimates. EBIT margins were down 150bps year-over-year, but above the firm's estimates. GE HealthCa raised the lower end of 2025 EPS guidance, but Flyrcado to be less than $30M in 2025 sales.
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
